Although considerable evidence implicates the MET-HGF axis as a therapeutic target in HNSCC [63], appropriate assays to detect aberrations in MET and its ligand HGF are lacking and further investigation is warranted. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.